NuSirt Biopharma, a Nashville, TN-based developer of therapeutics for people with chronic metabolic diseases, raised $6m in Series C financing of which $2m has been funded.
Backers included Hatteras Venture Partners, Mountain Group Partners and TriStar Technology Ventures.
The company intends to use the funds to expand research and development of its patented technology, which combines a naturally occurring amino acid, leucine, with existing pharmaceuticals, and accelerate a separate product targeting non-alcoholic fatty liver disease (NAFLD), including steatohepatitis (NASH).
Led by Joe C. Cook Jr., president and executive chairman, NuSirt Sciences has a technology platform that uses a patented combination of leucine, an essential amino acid, and existing human medicines targeted at diseases that may be addressed by activating sirtuin pathways. Its first technology application explores combining leucine with metformin, a Type 2 diabetes medication, to control blood sugar. The company is currently completing a Phase 2A study that is testing whether its technology combining leucine with low doses of metformin can effectively control glucose levels when compared to full dose metformin. Clinical study results are expected this summer.
The second program is focused on non-alcoholic fatty liver disease (NAFLD), a condition that is estimated to affect up to one-third of the general population.
FinSMEs
13/05/2015